Evidence map›Paper›PMID 42908035›Full record

ArticleBiology direct2026

Multiomics, multi-species profiling, and animal validation identify mitoxyperilysis as a conserved therapeutic target in metabolic dysfunction-associated steatohepatitis.

Hanjie Liu, Cong Qi, Ruixia Lu, Chuan An, Yangzhiyuan Wang, Shumiao Li, Rui Zhu, Xingzhong Feng, Huijuan Gao

Abstract read
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hanjie LiuTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.ORCID https://orcid.org/0009-0005-6495-4705
Cong QiTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Ruixia LuTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Chuan AnTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Yangzhiyuan WangTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Shumiao LiTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Rui ZhuTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Xingzhong FengTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. fengxz9797@sina.com.
Huijuan GaoTsinghua University Yuquan Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. gaohuijuanghj@126.com.ORCID https://orcid.org/0000-0002-2606-848X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsMetabolic dysfunction-associated steatohepatitis (MASH) is driven by complex intercellular communication and regulated cell death pathways. Mitoxyperilysis, a recently characterized form of regulated lytic cell death, remains poorly defined in MASH. Here, we integrated multiomics, cross-species transcriptomics, machine learning, and in vivo models to dissect mitoxyperilysis activation and its therapeutic relevance in MASH.

methodsSingle‑cell and spatial transcriptomic datasets from mouse and human MASH livers were analyzed. Cell-cell communication was inferred using CellChat, and metabolite‑mediated cell-cell communication (mCCC) was assessed with MEBOCOST. Mitoxyperilysis activity was scored via AUCell and AddModuleScore. Eleven machine learning classifiers identified transcriptomic signatures distinguishing MASH from controls, and key regulators were subjected to in silico knockout (scTenifoldKnk). A choline‑deficient, L‑amino acid‑defined high‑fat diet (CDAHFD) mouse model was used for in vivo validation.

resultsSingle‑cell profiling revealed that mitoxyperilysis activity was highly enriched in myeloid cells, particularly monocyte‑derived macrophages (Mo‑Macrophages) and neutrophils, and was strongly induced by high‑fat high‑sucrose diet. CellChat and mCCC analyses demonstrated that Mo‑Macrophages served as central hubs of rewired inflammatory and metabolic crosstalk in MASH. Spatial transcriptomics confirmed the expansion of pro‑inflammatory hepatocyte subsets and conserved upregulation of mitoxyperilysis components (e.g. BAX, TLR4, NINJ1) in both mouse and human MASH. Cross‑species profiling across mouse, rat, hamster, non‑human primate, and human datasets demonstrated evolutionarily conserved activation of the entire mitoxyperilysis pathway. Machine learning identified Bax as the sole overlapping driver gene linking diet‑induced transcriptomic signatures to mitoxyperilysis. In silico Bax ablation perturbed lipid metabolism and immune pathways. In CDAHFD-induced MASH mice with typical pathological phenotypes, core mitoxyperilysis genes were transcriptionally upregulated, and Bax/Bid/Bak1 upregulation was validated at the protein level. While RhoA mRNA increased, total RhoA protein remained stable, with its ubiquitination elevated and activity suppressed.

conclusionsMitoxyperilysis is an evolutionarily conserved, myeloid‑enriched pathway activated in MASH. Bax acts as a critical regulatory node, while RhoA is modulated via ubiquitination and functional suppression. Targeting this axis may provide a novel therapeutic strategy for MASH.

Indexed as

Fatty LiverMetabolic DiseasesAnimalsDisease Models, AnimalHumansMaleMiceMultiomicsTranscriptomeCross-species analysisMetabolic dysfunction-associated steatohepatitis (MASH)MitoxyperilysisSingle-cell transcriptomicsSpatial transcriptomics

Identifiers

PMID42908035
PMCPMC13688918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.